Breast Cancer

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Tanya Gupta, MD, shares factors informing frontline treatment approaches for metastatic hormone receptor–positive, HER2-negative breast cancer.

Aydah Alawadhi, MBBS, discusses the effect of obesity and overweight status on patient outcomes across subgroups of early-stage breast cancer.

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

Tess O’Meara, MD, MHS, and Kelsey H. Natsuhara, MD, discuss their presentations from the OncLive National Fellows Forum at SABCS.

Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.

Tanya Gupta, MD, details FDA-approved CDK4/6 inhibitors and considerations for selecting treatment in HR-positive, HER2-negative metastatic breast cancer.

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Coy Heldermon, MD, PhD, discusses a phase 1/2 trial design evaluating pharmacokinetics and safety of epidiferphane given with taxane chemotherapy in breast cancer.

Vepdegestrant improved PFS in ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer, but PFS was not improved in the ITT population.

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.